Comparative study of the efficacy of formulations containing fluconazole or paromomycin for topical treatment of infections by Leishmania (Leishmania) major and Leishmania (Leishmania) amazonensis

Parasitology Research

Volumn 100, Issue 6, 2007, Pages 1221-1226

  Mussi, Samuel Vidal ^a   Fernandes, Ana Paula ^a   Ferreira, Lucas Antonio Miranda ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOMER; FLUCONAZOLE; LAURETH 4; METHYL PARABEN; MYRISTIC ACID ISOPROPYL ESTER; PAROMOMYCIN; POLYOXYETHYLENE DERIVATIVE; PROPYLENE GLYCOL; SODIUM HYDROXIDE; UNCLASSIFIED DRUG; WATER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIMICROBIAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; EXPERIMENTAL INFECTION; FEMALE; LEISHMANIA; LEISHMANIA MAJOR; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN DEFECT; SKIN LEISHMANIASIS; SKIN ULCER; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; ULCER HEALING;

ADMINISTRATION, ORAL; ADMINISTRATION, TOPICAL; ANIMALS; ANTIPROTOZOAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUCONAZOLE; LEISHMANIA MAJOR; LEISHMANIASIS, CUTANEOUS; MICE; MICE, INBRED BALB C; PAROMOMYCIN;

ANIMALIA; LEISHMANIA AMAZONENSIS; LEISHMANIA MAJOR; MUS;

EID: 33947413563     PISSN: 09320113     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00436-006-0394-6     Document Type: Article

References (27)

1. Al-Abdely HM, Graybill JR, Loebenberg D, Melby PC (1999) Efficacy of the triazole SCH 56592 against Leishmania amazonensis and Leishmania donovani in experimental murine cutaneous and visceral leishmaniases. Antimicrob Agents Chemother 43:2910-2914
2. Alrajhi AA, Ibrahim EA, De Vol EB, Khairat M, Faris RM, Maguire JH (2002) Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major. N Engl J Med 346:891-895
3. Arana BA, Mendoza CE, Rizzo NR, Kroeger A (2001a) Randomized, controlled, double-blind trial of topical treatment of cutaneous leishmaniasis with paromomycin plus methylbenzethonium chloride ointment in Guatemala. Am J Trop Med Hyg 65:466-470
4. Arana B, Rizzo N, Diaz A (2001b) Chemotherapy of cutaneous leishmaniasis: a review. Med Microbiol Immunol 190:93-95
5. Armijos RX, Weigel MM, Calvopina M, Mancheno M, Rodriguez R (2004) Comparison of the effectiveness of two topical paromomycin treatments versus meglumine antimoniate for New World cutaneous leishmaniasis. Acta Trop 91:153-160
6. Ayub AC, Gomes ADM, Lima MVC, Vianna-Soares CD, Ferreira LAM (2006) Topical delivery of fluconazole: in vitro skin penetration and permeation using emulsions as dosage forms. Drug Dev Ind Pharm (in press)
7. Baron S, Laube S, Raafat F, Moss C (2004) Cutaneous leishmaniasis in a Kosovan child treated with oral fluconazole. Clin Exp Dermatol 29:546-547
8. Barral-Netto M, Barral A, Brodskyn C, Carvalho EM, Reed SG (1995) Cytotoxicity in human mucosal and cutaneous leishmaniasis. Parasite Immunol 17:21-28
9. Berman J (1997) Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years. Clin Infect Dis 24:684-703
10. Berman J (2003) Current treatment approaches to leishmaniasis. Curr Opin Infect Dis 16:397-401
11. Berman J (2005a) Recent developments in leishmaniasis: epidemiology, diagnosis, and treatment. Curr Infect Dis Rep 7:33-38
12. Berman J (2005b) Clinical status of agents being developed for leishmaniasis. Expert Opin Investig Drugs 14:1337-1346
13. Castro GA, Nascimento DS, Nunan EA, Fernandes AP, Ferreira LAM (2003) In vitro skin permeation of paromomycin from topical formulations across normal and stripped hairless mouse skin. STP Pharma Sci 13:203-208
14. Croft SL, Coombs GH (2003) Leishmaniasis - current chemotherapy and recent advances in the search for novel drugs. Trends Parasitol 19:502-508
15. Croft SL, Seifert K, Yardley V (2006) Current scenario of drug development for leishmaniasis. Indian J Med Res 123:399-410
16. El-On J, Jacobs GP, Weinrauch L (1988) Topical chemotherapy of cutaneous leishmaniasis. Parasitol Today 4:76-81
17. Fernandes AP, Carvalho FA, Tavares CA, Santiago HC, Castro GA, Tafuri WL, Ferreira LA, Gazzinelli RT (2001) Combined interleukin-12 and topical chemotherapy for established leishmaniasis drastically reduces tissue parasitism and relapses in susceptible mice. J Infect Dis 183:1646-1652
18. Grevelink SA, Lerner EA (1996) Leishmaniasis. J Am Acad Dermatol 34:257-272
19. Goncalves GS, Fernandes AP, Souza RC, Cardoso JE, de Oliveira-Silva F, Maciel FC, Rabello A, Ferreira LA (2005) Activity of a paromomycin hydrophilic formulation for topical treatment of infections by Leishmania (Leishmania) amazonensis and Leishmania (Viannia) braziliensis. Acta Trop 93:161-167
20. Grogl M, Schuster BG, Ellis WY, Berman JD (1999) Successful topical treatment of murine cutaneous leishmaniasis with a combination of paromomycin (Aminosidine) and gentamicin. J Parasitol 85:354-359
21. Laffitte E, Genton B, Panizzon RG (2005) Cutaneous leishmaniasis caused by Leishmania tropica: treatment with oral fluconazole. Dermatology 210:249-251
22. Neal RA, Allen S, McCoy N, Olliaro P, Croft SL (1995) The sensitivity of Leishmania species to aminosidine. J Antimicrob Chemother 35:577-584
23. Romero GA, Guerra MV, Paes MG, Macedo VO (2001) Comparison of cutaneous leishmaniasis due to Leishmania (Viannia) braziliensis and L. (V.) guyanensis in Brazil: therapeutic response to meglumine antimoniate. Am J Trop Med Hyg 65:456-465
24. Soto J, Fuya P, Herrera R, Berman J (1998) Topical paromomycin/ methylbenzethonium chloride plus parenteral meglumine antimonate as treatment for American cutaneous leishmaniasis: controlled study. Clin Infect Dis 26:56-58
25. Soto J, Toledo JT, Gutierrez P, Arboleda M, Nicholls RS, Padilla JR, Berman JD, English CK, Grogl M (2002) Treatment of cutaneous leishmaniasis with a topical antileishmanial drug (WR279396): phase 2 pilot study. Am J Trop Med Hyg 66:147-151
26. Sundar S (2001) Treatment of visceral leishmaniasis. Med Microbiol Immunol 190:89-92
27. Wortmann G, Miller RS, Oster C, Jackson J, Aronson N (2002) A randomized, double-blind study of the efficacy of a 10 or 20-day course of sodium stibogluconate for treatment of cutaneous leishmaniasis in United States military personnel. Clin Infect Dis 35:261-267